An Open Label Trial of STRIBILD(TM) (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate) for ARV-naive HIV-2 Infected Adults in Dakar, Senegal

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary)
Indications HIV-2 infections
Focus Adverse reactions; Therapeutic Use
Acronyms Stribild HIV-2

17 Apr 2018 Results published in the Clinical Infectious Diseases.
26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science
25 May 2017 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com